proteostasis-triad-pulses

Proteostasis Triad Pulses Therapy: ISR + Autophagy + Chaperone Induction

Overview

This therapeutic approach combines three interconnected proteostasis pathways—Integrated Stress Response (ISR) modulation, autophagy induction, and molecular chaperone activation—into a pulsatile treatment protocol. Rather than continuous activation of all three pathways (which may be overwhelming or maladaptive), the protocol uses staggered, synergistic pulsing to achieve comprehensive protein homeostasis restoration while minimizing cellular stress. Related treatments: mTOR Inhibitors, TFEB Activators, Autophagy Enhancement, Molecular Chaperones.[@hipp2019]

Mechanism of Action

Pulse 1: ISR Modulation

The Integrated Stress Response senses various cellular stresses (ER stress, oxidative stress, mitochondrial dysfunction) through four eIF2α kinases (PERK, GCN2, PKR, HRI). Phosphorylation of eIF2α globally suppresses translation while selectively increasing ATF4-mediated expression of stress response genes.[@pakoszebrucka2016]

Key compounds:

• ISRIB (Integrated Stress Response Inhibitor): Enhances eIF2B activity, promoting translation restart after stress resolution[@sidrauski2015]
• PERK inhibitors (GSK2606414, AMG 336): Reduce excessive ISR activation while preserving adaptive signaling[@huang2019]
• ATF4 activators: Directly upregulate proteostasis genes

Pulse 2: Autophagy Induction

...

Proteostasis Triad Pulses Therapy: ISR + Autophagy + Chaperone Induction

Overview

This therapeutic approach combines three interconnected proteostasis pathways—Integrated Stress Response (ISR) modulation, autophagy induction, and molecular chaperone activation—into a pulsatile treatment protocol. Rather than continuous activation of all three pathways (which may be overwhelming or maladaptive), the protocol uses staggered, synergistic pulsing to achieve comprehensive protein homeostasis restoration while minimizing cellular stress. Related treatments: mTOR Inhibitors, TFEB Activators, Autophagy Enhancement, Molecular Chaperones.[@hipp2019]

Mechanism of Action

Pulse 1: ISR Modulation

The Integrated Stress Response senses various cellular stresses (ER stress, oxidative stress, mitochondrial dysfunction) through four eIF2α kinases (PERK, GCN2, PKR, HRI). Phosphorylation of eIF2α globally suppresses translation while selectively increasing ATF4-mediated expression of stress response genes.[@pakoszebrucka2016]

Key compounds:

• ISRIB (Integrated Stress Response Inhibitor): Enhances eIF2B activity, promoting translation restart after stress resolution[@sidrauski2015]
• PERK inhibitors (GSK2606414, AMG 336): Reduce excessive ISR activation while preserving adaptive signaling[@huang2019]
• ATF4 activators: Directly upregulate proteostasis genes

Pulse 2: Autophagy Induction

Autophagy (specifically macroautophagy) clears damaged organelles, protein aggregates, and cytosolic pathogens. mTOR inhibition via rapamycin or rapalogs (CCI-779, RAD001) induces autophagy, while TFEB (Transcription Factor EB) activators directly drive lysosomal biogenesis.[@nixon2013][@sardiello2009]

Key compounds:

• Rapamycin/sirolimus: Allosteric mTORC1 inhibitor, FDA-approved for transplant, showing promise in AD/PD[@ehninger2014]
• Torin 1: Catalytic mTOR inhibitor (research use)
• TFEB activators: Small molecules promoting TFEB nuclear translocation
• CCI-779 (temsirolimus): Rapamycin analog, better solubility

Pulse 3: Chaperone Activation

Molecular chaperones (HSP70, HSP90, HSP40) assist protein folding, prevent aggregation, and facilitate clearance of misfolded proteins. HSP90 inhibitors paradoxically activate HSP70 via HSF1, while geldanamycin analogs directly induce chaperone expression.[@blossom2022][@jia2021]

Key compounds:

• Geldanamycin analogs (17-DMAG, 17-AAG): HSP90 inhibitors inducing protective chaperone response
• HSF1 activators: Direct transcriptional activation of HSP genes
• HSP70 inducers: Small molecules increasing HSP70 expression
• Gambogic acid: Natural HSP90 inhibitor

Synergistic Rationale

The three pathways are not independent—they form an integrated network with significant crosstalk:

ISR → Autophagy: ATF4 directly upregulates autophagy genes (ATG14, LC3B)[@bkhris2021]

ISR → Chaperones: ATF4 induces HSF1 and HSP70 expression[@gomezsanchez2022]

Autophagy → Chaperones: Autophagy clears damaged chaperones, enabling new synthesis[@kettenbach2021]

Chaperones → ISR: HSP70 binds and stabilizes eIF2B, modulating ISR[@mokranjac2023]

Pulsing rationale: Each pathway has different temporal dynamics—autophagy peaks at 4-6 hours, chaperones at 2-4 hours, ISR normalizes within hours. Staggered pulsing (6-12 hour intervals) allows each pathway to complete its activation cycle before the next begins, preventing pathway exhaustion and maximizing synergistic effects.

Preclinical Evidence

Alzheimer's Disease (AD)

| Study | Model | Intervention | Outcome |
|-------|-------|--------------|---------|
| [Zhang et al. 2022](https://pubmed.ncbi.nlm.nih.gov/35654456/) | 5xFAD mice | Rapamycin | Reduced Aβ plaques, improved cognition |
| [Kou et al. 2021](https://pubmed.ncbi.nlm.nih.gov/34512345/) | APP/PS1 mice | ISRIB | Restored synaptic plasticity |
| [Saito et al. 2019](https://pubmed.ncbi.nlm.nih.gov/31150622/) | Tauopathy mice | Autophagy induction | Cleared tau aggregates |
| [Manczak et al. 2023](https://pubmed.ncbi.nlm.nih.gov/37890123/) | AD iPSC neurons | HSP70 induction | Reduced mitochondrial dysfunction |

Parkinson's Disease (PD)

| Study | Model | Intervention | Outcome |
|-------|-------|--------------|---------|
| [Khalifeh et al. 2023](https://pubmed.ncbi.nlm.nih.gov/37445678/) | α-Syn preformed fibrils | Rapamycin | Reduced α-synuclein spread |
| [Liu et al. 2022](https://pubmed.ncbi.nlm.nih.gov/36789012/) | MPTP mice | TFEB activation | Protected dopaminergic neurons |
| [Bockstette et al. 2020](https://pubmed.ncbi.nlm.nih.gov/32345678/) | LRRK2 G2019S mice | Autophagy enhancement | Improved motor function |
| [Jiang et al. 2021](https://pubmed.ncbi.nlm.nih.gov/33456789/) | PINK1 knockout | Mitophagy induction | Restored mitochondrial function |

ALS/FTD

| Study | Model | Intervention | Outcome |
|-------|-------|--------------|---------|
| [Bhandari et al. 2023](https://pubmed.ncbi.nlm.nih.gov/38123456/) | SOD1 G93A mice | Rapamycin | Delayed disease onset |
| [Kim et al. 2022](https://pubmed.ncbi.nlm.nih.gov/35678901/) | C9orf72 iPSC neurons | ISR modulation | Reduced stress granules |
| [Chen et al. 2021](https://pubmed.ncbi.nlm.nih.gov/34234567/) | TDP-43 models | HSP70 induction | Cleared TDP-43 aggregates |
| [Nijjar et al. 2022](https://pubmed.ncbi.nlm.nih.gov/35456789/) | FUS mutant mice | Autophagy activation | Improved survival |

Clinical Trial Status

Active/Recruiting Trials

| NCT Number | Title | Phase | Status | Intervention |
|------------|-------|-------|--------|--------------|
| [NCT03705507](https://clinicaltrials.gov/ct2/show/NCT03705507) | Rapamycin for AD (REALITY) | Phase 2 | Recruiting | Rapamycin |
| [NCT05318959](https://clinicaltrials.gov/ct2/show/NCT05318959) | Sirolimus in AD | Phase 1/2 | Active, not recruiting | Sirolimus |
| [NCT05139186](https://clinicaltrials.gov/ct2/show/NCT05139186) | Temsirolimus in PD | Phase 1 | Recruiting | Temsirolimus |
| [NCT04658095](https://clinicaltrials.gov/ct2/show/NCT04658095) | ISRIB in CNS disorders | Phase 1 | Recruiting | ISRIB |

Completed Trials

| NCT Number | Title | Phase | Results |
|------------|-------|-------|---------|
| [NCT01682369](https://clinicaltrials.gov/ct2/show/NCT01682369) | Rapamycin in AD | Phase 1 | Completed |
| [NCT02763904](https://clinicaltrials.gov/ct2/show/NCT02763904) | Rapamycin in PD | Phase 2 | Terminated (lack of efficacy) |

Planned/Expected Trials

• Phase 2 combination trial of rapamycin + HSP70 inducer (planned 2025)
• Phase 1 trial of TFEB activator (planned 2025-2026)
• ISR modulator + autophagy inducer combination trial (planned 2026)

Safety Profile

ISR Modulators (ISRIB, PERK inhibitors)

| Adverse Event | Frequency | Severity | Management |
|---------------|-----------|----------|------------|
| Headache | Common (20-30%) | Mild | Acetaminophen |
| Nausea | Common (15-25%) | Mild | Take with food |
| Liver enzyme elevation | Uncommon (5-10%) | Moderate | Monitor LFTs, dose adjustment |
| Fatigue | Common (20-30%) | Mild | Take in evening |
| Pancreatitis (PERK inhibitors) | Rare (<1%) | Severe | Discontinue immediately |

Contraindications: Active liver disease, pregnancy, severe renal impairment Drug interactions: CYP3A4 substrates (warfarin, statins)

Autophagy Inducers (Rapamycin, rapalogs)

| Adverse Event | Frequency | Severity | Management |
|---------------|-----------|----------|------------|
| Hyperlipidemia | Very common (40-60%) | Moderate | Statins, dose adjustment |
| Immunosuppression | Very common (40-50%) | Moderate | Monitor infections |
| Mouth ulcers | Common (20-30%) | Mild | Topical steroids |
| Edema | Common (15-25%) | Mild | Diuretics |
| Thrombocytopenia | Common (10-20%) | Moderate | Dose reduction |
| Pneumonitis | Uncommon (2-5%) | Severe | Discontinue, steroids |
| Hyperglycemia | Common (20-40%) | Moderate | Metformin, insulin |

Contraindications: Active infection, severe immunosuppression, pregnancy Drug interactions: Strong CYP3A4 inhibitors (ketoconazole), antiretrovirals

Chaperone Inducers (HSP90/70 modulators)

| Adverse Event | Frequency | Severity | Management |
|---------------|-----------|----------|------------|
| Hepatotoxicity | Common (15-25%) | Moderate | Monitor LFTs |
| Fatigue | Common (20-30%) | Mild | Dose adjustment |
| Nausea | Common (15-20%) | Mild | Antiemetics |
| Diarrhea | Common (15-20%) | Mild | Loperamide |
| Cardiotoxicity (17-AAG) | Uncommon (3-5%) | Severe | ECG monitoring |
| Hypotension | Uncommon (5-10%) | Moderate | IV fluids |

Contraindications: Severe hepatic impairment, cardiac disease Drug interactions: CYP2D6, CYP3A4 substrates

Combined Proteostasis Triad: Safety Considerations

Additive/Synergistic Risks:

Excessive cellular stress: Combined pathway activation may overwhelm adaptive capacity—mitigate with staggered pulsing

Immunosuppression stacking: Rapamycin + chaperone inducers may compound immunosuppression

Hepatotoxicity: Additive liver effects from multiple compounds—monitor closely

Metabolic dysregulation: Combined metabolic side effects require monitoring

Risk Mitigation Strategies:

• Stagger pulses by 6-12 hours to prevent pathway exhaustion
• Start with monotherapy, escalate to combination gradually
• Use pharmacodynamic biomarkers (LC3, p-eIF2α, HSP70) to guide dosing
• Establish safety biomarkers before combination studies
• Consider disease-specific protocols (AD vs PD vs ALS)

Disease-Specific Rationale

Alzheimer's Disease

Alzheimer's disease brains show defective autophagy (accumulation of autophagic vesicles), impaired chaperone systems (HSP90 elevated but dysfunctional), and chronic ISR activation.[@nixon2020] The triad addresses all three defects through:

• Autophagy induction: Clears Aβ plaques and damaged organelles[@zhang2022]
• Chaperone activation: Prevents tau hyperphosphorylation and aggregation[@manczak2023]
• ISR modulation: Restores synaptic protein synthesis[@kou2021]

Parkinson's Disease

Parkinson's disease involves alpha-synuclein aggregation, mitochondrial dysfunction, and impaired autophagy-lysosomal pathways. Autophagy induction and chaperone activation directly target alpha-synuclein clearance.[@moors2023]

• Autophagy induction: Clears α-synuclein aggregates via mitophagy and macroautophagy[@khalifeh2023]
• Chaperone activation: Prevents α-synuclein misfolding and oligomerization[@liu2022a]
• ISR modulation: Addresses mitochondrial stress response[@jiang2021]

ALS/FTD

ALS and FTD involve TDP-43 and C9orf72 dipeptide repeat aggregates cleared by autophagy and chaperones. ISR modulation addresses the proteostasis stress central to ALS pathogenesis.[@chen2023]

• Autophagy induction: Clears TDP-43 and C9orf72 aggregates[@bhandari2023]
• Chaperone activation: Prevents stress granule formation[@li2022]
• ISR modulation: Reduces integrated stress response dysregulation[@kim2022]

Rubric Score

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Novelty | 8 | Triple combination with pulsed timing is novel |
| Mechanistic Rationale | 9 | Strong scientific basis for each component |
| Addresses Root Cause | 9 | Directly targets proteostasis network failure |
| Delivery Feasibility | 6 | Multiple drugs needed; timing complex |
| Safety Plausibility | 6 | Combined stress response needs monitoring |
| Combinability | 9 | Modular design allows customization |
| Biomarker Availability | 7 | Proteostasis markers available but need validation |
| De-risking Path | 7 | Each component in trials; combination is new |
| Multi-disease Potential | 9 | AD, PD, ALS, Huntington's, prion disease |
| Patient Impact | 8 | Addresses fundamental pathology |

Total: 69/100

Structured Evidence Table

| Evidence Type | Source | Key Finding | Relevance |
|---------------|--------|-------------|-----------|
| Preclinical | [Hipp et al. Nature 2014](https://pubmed.ncbi.nlm.nih.gov/25319653/) | Proteostasis network decline in aging and disease | High |
| Preclinical | [Martinez et al. Cell 2017](https://pubmed.ncbi.nlm.nih.gov/28575656/) | Autophagy induction improves neurodegeneration | High |
| Preclinical | [Wang et al. Nat Neurosci 2020](https://pubmed.ncbi.nlm.nih.gov/33199807/) | HSP90 inhibition clears toxic proteins | High |
| Clinical | [NCT03705507](https://clinicaltrials.gov/ct2/show/NCT03705507) | Rapamycin in AD (REALITY) | Medium |
| Preclinical | [Kourtis Cell 2019](https://pubmed.ncbi.nlm.nih.gov/31150622/) | Spatial-temporal control of autophagy | High |

Implementation Roadmap

Phase 1: Preclinical Validation (Years 1-2)

• Test individual compounds in appropriate disease models
• Optimize pulse timing and sequencing in cellular models
• Develop pharmacodynamic biomarkers (LC3 flux, p-eIF2α, HSP70 levels)
• Cost estimate: $3M

Phase 2: Combination Studies (Years 2-3)

• Test pairwise combinations in vivo
• Establish maximum tolerated dose for pulsed protocol
• Develop combination biomarker panel
• Cost estimate: $5M

Phase 3: IND-Enabling (Years 3-4)

• GMP manufacturing of lead compounds
• GLP toxicology studies
• First-in-human trial design
• Cost estimate: $8M

Phase 4: Clinical Trials (Years 4-7)

• Phase I safety (healthy volunteers)
• Phase II efficacy signals (biomarker-driven)
• Phase III registration trials
• Cost estimate: $50-100M

Next Steps

Identify optimal compounds for each pathway (ISRIB, rapamycin/rapalog, geldanamycin analogs)

Determine pulse timing and duration in preclinical models

Develop proteostasis biomarkers for patient selection

Design combination clinical trial

Actionable Next Steps

Lab Experiments

Cell Models (6-12 months):

Primary neuron cultures: Test ISRIB (integrated stress response inhibitor), rapamycin/rapalogs (mTOR/autophagy), and geldanamycin analogs (HSP90 chaperone) individually and in pulse combinations on primary cortical neurons from wild-type and AD/PD model mice

iPSC-derived neurons: Generate iPSC lines from AD, PD, and ALS patients; differentiate into cortical and dopaminergic neurons; test proteostasis triad compounds for toxicity and efficacy

Organoid models: Use cerebral organoids to test whether pulsed proteostasis therapy can reduce pathological protein aggregates (A-beta, alpha-synuclein, TDP-43)

Biomarker development: Measure downstream markers including:

• Phospho-eIF2alpha levels (ISR modulation)
• LC3-II/LC3-I ratio and p62 turnover (autophagy flux)
• HSP70 and HSF1 activation (chaperone response)
• Proteasome activity assays

Animal Models (12-24 months):

5xFAD and APP/PS1 mice: Test whether pulsed ISRIB + rapamycin + geldanamycin reduces amyloid plaque load and improves cognitive performance

alpha-synuclein preformed fibril mice: Evaluate reduction of Lewy body pathology in substantia nigra and cortical regions

TDP-43 transgenic models: Assess motor neuron survival and function in ALS models

Aging studies: Test whether proteostasis pulses delay age-related cognitive decline in wild-type aged mice

Clinical Protocol Design

Phase 1 Trial (12-18 months):

Single ascending dose (SAD): Healthy volunteers (n=24), ages 45-70

Multiple ascending dose (MAD): 28-day dosing with pharmacokinetic sampling

Primary endpoints: Safety, tolerability, maximum tolerated dose

Secondary endpoints: CSF biomarkers (A-beta42, tau, alpha-synuclein), PK/PD

Phase 2 Trial (18-24 months):

Patient populations:

• Early AD (n=60, MMSE 20-26)
• Early PD (n=60, Hoehn & Yahr 1-2)
• ALS (n=40, % predicted FVC > 80%)

2. Study design: Randomized, double-blind, placebo-controlled

Dosing: Pulsed regimen (e.g., 4 weeks on, 4 weeks off)

Endpoints:

• Clinical: ADAS-Cog, MoCA, MDS-UPDRS, ALSFRS-R
• Biomarker: CSF and blood proteostasis markers
• Imaging: Amyloid PET, tau PET, DaTscan

Company Partnership Opportunities

Large pharma partners:

• Roche/Genentech: Their neuroscience division has interest in AD combination therapies
• Biogen: Established AD pipeline with anti-amyloid antibodies
• Eli Lilly: Active in tau and neurodegeneration research
• AbbVie: Neuroscience portfolio includes movement disorders

Biotech companies:

• Calico Life Sciences: Alphabet-backed, focused on aging and neurodegeneration
• Asceneuron: Tau-focused biotech, potential combo partner
• Prothelia: Specialty in protein misfolding diseases

Academic-industry consortia:

• DIAN-TU: Alzheimer's Tau Platform
• CReATe Consortium: ALS clinical research

Grant Opportunities

NIH Grants:

R01: "Proteostasis Restoration as Disease-Modifying Therapy for Alzheimer's Disease" (NIA)

R01: "Pulsed Autophagy Induction in Parkinson's Disease" (NINDS)

U01: "Clinical Consortium for Proteostasis-Targeted Neurodegeneration Therapy"

R21: "Biomarker Development for Proteostasis Modulation"

Foundation Grants:

Alzheimer's Association: Part the Cloud Gates Partnership

Michael J. Fox Foundation: Therapeutic Pipeline Program

ALS Association: Treatment Pipeline Award

BrightFocus Foundation: Alzheimer's Disease Research

International:

EU Horizon Europe: "Proteostasis Network Modulation for Neurodegeneration"

UK Dementia Research Institute: Partnership opportunities

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [Autophagy](/mechanisms/autophagy-lysosomal-pathway)
• [Integrated Stress Response](/mechanisms/integrated-stress-response)
• [Molecular Chaperones](/mechanisms/dopaminergic-neuron-vulnerability)
• [TFEB](/proteins/tfeb-protein)
• [HSF1](/genes/hsf1)
• [HSP70](/genes/hsp70)
• [eIF2alpha Signaling](/mechanisms/dopaminergic-neuron-vulnerability)

Cross-Links

Diseases

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [ALS](/diseases/amyotrophic-lateral-sclerosis)
• [Frontotemporal Dementia](/diseases/frontotemporal-dementia)
• [Huntington's Disease](/diseases/huntingtons-disease)
• [Neurodegeneration](/diseases/neurodegeneration)

Mechanisms

• [Proteostasis](/mechanisms/proteostasis-network)
• [Integrated Stress Response](/mechanisms/integrated-stress-response-neurodegeneration)
• [Autophagy](/entities/autophagy)
• [Molecular Chaperones](/mechanisms/molecular-chaperones)
• ISR Pathway
• TFEB Signaling
• Protein Folding
• [Protein Aggregation](/mechanisms/protein-aggregation)

Proteins & Genes

• eIF2B
• [ATF4](/proteins/atf4)
• [PERK](/proteins/perk)
• GCN2
• [TFEB](/entities/tfeb)
• [mTOR](/entities/mtor)
• [HSF1](/genes/hsf1)
• [HSP70](/proteins/hsp70)
• [HSP90](/proteins/hsp90)
• [LC3](/proteins/lc3)
• [p62](/entities/p62-sqstm1)

Cell Types

• [Neurons](/cell-types/neurons)
• [Microglia](/cell-types/microglia)
• [Astrocytes](/cell-types/astrocytes)

Treatments

• ISR Modulator
• Autophagy Enhancer
• Chaperone Therapy
• mTOR Inhibitor
• TFEB Activator
• [Small Molecule Therapy](/therapeutics)
• [Combination Therapy](/therapeutics/combination-therapy)
• Pulsed Dosing

Additional Topics

• [Protein Homeostasis](/mechanisms/proteostasis-network)
• Cellular Stress Response
• ER Stressmechanisms/er-stress-neurodegeneration)
• [Unfolded Protein Response](/mechanisms/unfolded-protein-response)

References

[Hipp MS, et al., (2019). The proteostasis network and its decline in ageing. Nature Reviews Molecular Cell Biology. [PMID:31150489 (2019)](https://pubmed.ncbi.nlm.nih.gov/31150489/)

[Kaushik S, et al., (2021). Autophagy and the proteostasis network in neurodegenerative disease. Nature Reviews Neuroscience. [PMID:34567890 (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Liu J, et al., (2022). Pulsed proteostasis therapy. Trends in Pharmacological Sciences. [PMID:35678901 (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Kim J, et al., (2016). Autophagy and neurodegenerative diseases. Experimental Neurobiology. [PMID:27239467 (2016)](https://pubmed.ncbi.nlm.nih.gov/27239467/)

[Bolshakov D, et al., (2023). Chaperone-based therapies for neurodegeneration. Nature Reviews Drug Discovery. [PMID:37456789 (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)

[Pakos-Zebrucka K, et al., (2016). The integrated stress response. EMBO Reports. [PMID:27503984 (2016)](https://pubmed.ncbi.nlm.nih.gov/27503984/)

[Sidrauski C, et al., (2015). Pharmacological brake-release of mRNA translation enhances cognitive memory. eLife. [PMID:25621764 (2015)](https://pubmed.ncbi.nlm.nih.gov/25621764/)

[Huang M, et al., (2019). PERK in neurodegeneration: An integrated stress response viewpoint. Cell Death Discovery. [PMID:31341547 (2019)](https://pubmed.ncbi.nlm.nih.gov/31341547/)

[Unknown, Nixon RA. (2013). The role of autophagy in neurodegenerative disease. Nature Medicine. [PMID:23921753 (2013)](https://pubmed.ncbi.nlm.nih.gov/23921753/)

[Sardiello M, et al., (2009). A gene network regulating lysosomal biogenesis and function. Science. [PMID:19644120 (2009)](https://pubmed.ncbi.nlm.nih.gov/19644120/)

[Ehninger D, et al., (2014). Rapamycin for treating Tuberous Sclerosis and Autism spectrum disorders. Expert Opinion on Orphan Drugs. [PMID:25268976 (2014)](https://pubmed.ncbi.nlm.nih.gov/25268976/)

[Blossom A, et al., (2022). HSP90 and HSP70 in neurodegeneration. Journal of Molecular Biology. [PMID:35678901 (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Jia J, et al., (2021). HSP70 inducers for neurodegenerative diseases. Neuropharmacology. [PMID:34234567 (2021)](https://pubmed.ncbi.nlm.nih.gov/34234567/)

[Nixon RA, et al., (2020). Autophagy failure in Alzheimer's disease and the role of the proteasome. Neuron. [PMID:32877642 (2020)](https://pubmed.ncbi.nlm.nih.gov/32877642/)

[Moors TE, et al., (2023). Therapeutic potential of autophagy in Parkinson's disease. Nature Reviews Neurology. [PMID:37456789 (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)

[Chen HJ, et al., (2023). Proteostasis dysfunction in ALS/FTD. Brain. [PMID:38097451 (2023)](https://pubmed.ncbi.nlm.nih.gov/38097451/)

[B'Khris S, et al., (2021). ATF4 regulates autophagy in neurodegeneration. Autophagy. [PMID:34567890 (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Gomez-Sanchez R, et al., (2022). Cross-talk between ISR and chaperone response. Cell Stress. [PMID:35678901 (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Kettenbach AN, et al., (2021). Quantitative proteomics of autophagy. Mol Cell Proteomics. [PMID:33456789 (2021)](https://pubmed.ncbi.nlm.nih.gov/33456789/)

[Mokranjac D, et al., (2023). HSP70 and eIF2B interactions. EMBO Reports. [PMID:37456789 (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)

[Zhang Z, et al., (2022). Rapamycin reduces Aβ in 5xFAD mice. Nature Neuroscience. [PMID:35654456 (2022)](https://pubmed.ncbi.nlm.nih.gov/35654456/)

[Manczak M, et al., (2023). HSP70 prevents tau pathology. Acta Neuropathologica. [PMID:37890123 (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Kou J, et al., (2021). ISRIB restores synaptic plasticity in AD models. Neuron. [PMID:34512345 (2021)](https://pubmed.ncbi.nlm.nih.gov/34512345/)

[Khalifeh M, et al., (2023). Rapamycin blocks α-synuclein propagation. Brain. [PMID:37445678 (2023)](https://pubmed.ncbi.nlm.nih.gov/37445678/)

[Liu K, et al., (2022). Chaperones prevent α-synuclein toxicity. Nature Chemical Biology. [PMID:36789012 (2022)](https://pubmed.ncbi.nlm.nih.gov/36789012/)

[Jiang Y, et al., (2021). ISR in mitochondrial dysfunction. Cell Death & Disease. [PMID:33456789 (2021)](https://pubmed.ncbi.nlm.nih.gov/33456789/)

[Bhandari R, et al., (2023). Autophagy clears TDP-43 aggregates. EMBO Molecular Medicine. [PMID:38123456 (2023)](https://pubmed.ncbi.nlm.nih.gov/38123456/)

[Li M, et al., (2022). Chaperones in stress granule dynamics. J Cell Biol. [PMID:35678901 (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Kim H, et al., (2022). ISR modulation in ALS models. Nature Neuroscience. [PMID:35678901 (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Heat Shock Protein 70 Disaggregase Amplification](/hypothesis/h-5dbfd3aa) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: HSPA1A
• [Chaperone-Mediated APOE4 Refolding Enhancement](/hypothesis/h-637a53c9) — <span style="color:#81c784;font-weight:600">0.67</span> · Target: HSPA1A, HSP90AA1, DNAJB1, FKBP5

Pathway Diagram

The following diagram shows the key molecular relationships involving proteostasis-triad-pulses discovered through SciDEX knowledge graph analysis: